Severe hepatopulmonary syndrome with hypoxemia refractory to liver transplant: Recovery after 67 days of ECMO support

Int J Artif Organs. 2022 Jan;45(1):121-123. doi: 10.1177/0391398821989067. Epub 2021 Jan 21.

Abstract

Hepatopulmonary syndrome (HPS) is a complication of end stage liver disease (ESLD) and is manifested by severe hypoxemia, which usually responds to liver transplantation (LT). As compared to patients undergoing LT for other etiologies, patients with HPS present an increased risk of postoperative morbidity and mortality. There is no effective treatment for patients whose hypoxemia does not respond to LT. This subset of patients is at a highly increased risk of death. There are very few reports on the use of extracorporeal membrane oxygenation (ECMO) in this setting with rapid response. However, there is no prior report of ECMO utilization for longer than 4 weeks. We present the case of a 17 year-old male patient who underwent LT for ESLD secondary to chronic portal vein thrombosis and HPS. He received a liver from a deceased donor and presented with severe HPS after LT, requiring ECMO support for 67 days. The patient was discharged home and is breathing in ambient air. He is currently asymptomatic and has a normal liver function.

Keywords: Artificial lung & respiratory support; ECMO; Intravascular oxygenators; Liver transplantation; apheresis & detoxification techniques; artificial kidney; hepatopulmonary syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • End Stage Liver Disease*
  • Extracorporeal Membrane Oxygenation*
  • Hepatopulmonary Syndrome* / diagnosis
  • Hepatopulmonary Syndrome* / etiology
  • Hepatopulmonary Syndrome* / therapy
  • Humans
  • Hypoxia / etiology
  • Hypoxia / therapy
  • Liver Transplantation* / adverse effects
  • Male